{
  "docId": "019de073-8568-725b-9a17-a64262808fc8",
  "docSlug": "d872feff7a8967ecac479e446ba0e3da",
  "documentTitle": "Context Therapeutics | Investor Presentation Deck | 25 slides",
  "authorId": "context-therapeutics",
  "authorName": "Context Therapeutics",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-09-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 12,
  "pageCount": 25,
  "prevPage": 11,
  "nextPage": 13,
  "slideType": "appendix_methodology",
  "function": "present_framework",
  "density": "balanced",
  "nDataPoints": 5,
  "notes": "The slide outlines a clinical trial protocol using a sequential phase design.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de073-8568-725b-9a17-a64262808fc8/12",
  "deckHref": "/decks/019de073-8568-725b-9a17-a64262808fc8",
  "deckJsonHref": "/decks/019de073-8568-725b-9a17-a64262808fc8.json",
  "deckAnchorHref": "/decks/019de073-8568-725b-9a17-a64262808fc8#slide-12",
  "components": [
    {
      "bbox": {
        "h": 0.3,
        "w": 0.9,
        "x": 0.05,
        "y": 0.55
      },
      "kind": "diagram",
      "text": "Patient Population: Prior therapy with CDK4/6 inhibitor required, No prior chemotherapy in metastatic setting permitted, ≥ 50% of patients will have ESR1 mutation -> Phase 1b: Dose escalation, 12-28 patients, 4 cohorts -> Phase 2: ~45 patients",
      "attrs": null,
      "subkind": "process",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "81c2e24e-d874-48d1-85ff-defa14bc370a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.6,
        "x": 0.05,
        "y": 0.18
      },
      "kind": "list",
      "text": "Indication: ER+,PR+,HER2- advanced or metastatic breast cancer\nStudy: Phase 1b (n=12-28) / Phase 2 (n=45)\nPrimary Endpoint: overall response rate (ORR)\nSecondary Endpoint: progression free survival (PFS), clinical benefit rate (CBR)\nSites: US only, 16-19 sites",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e03e1c55-57d1-4630-9514-cc4ca90f1255",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.9,
        "x": 0.05,
        "y": 0.07
      },
      "kind": "title",
      "text": "Phase 1b/2 (ELONA Trial) – Designed to Evaluate Combination Efficacy and Tolerability",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0740b96e-2dd2-4999-86f1-1f0c7f6a5b01",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "clinical-trial-design",
      "slug": null,
      "matchId": "ba6090ff-e541-46fb-9df0-dd8d8163cfda",
      "evidence": "Sequential phase structure (1b to 2) with defined patient population and endpoints.",
      "confidence": 0.8
    }
  ],
  "arcBeats": [],
  "loops": [
    {
      "to": 24,
      "from": 11,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "6f563f0a-bba6-40be-8cea-242e5c29e44d",
      "evidence": "Slides 11-24 outline the potential of ONA-XR and CLDN6xCD3 Bispecific Antibody Program",
      "position": 0,
      "objective": "Highlight the benefits of investment in Context Therapeutics",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.7,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}